217 related articles for article (PubMed ID: 11808966)
1. Are ulcers a marker for invasive carcinoma in Barrett's esophagus? Data from a diagnostic variability study with clinical follow-up.
Montgomery E; Bronner MP; Greenson JK; Haber MM; Hart J; Lamps LW; Lauwers GY; Lazenby AJ; Lewin DN; Robert ME; Washington K; Goldblum JR
Am J Gastroenterol; 2002 Jan; 97(1):27-31. PubMed ID: 11808966
[TBL] [Abstract][Full Text] [Related]
2. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.
Montgomery E; Goldblum JR; Greenson JK; Haber MM; Lamps LW; Lauwers GY; Lazenby AJ; Lewin DN; Robert ME; Washington K; Zahurak ML; Hart J
Hum Pathol; 2001 Apr; 32(4):379-88. PubMed ID: 11331954
[TBL] [Abstract][Full Text] [Related]
3. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
[TBL] [Abstract][Full Text] [Related]
4. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
[TBL] [Abstract][Full Text] [Related]
5. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Dorer R; Odze RD
Am J Surg Pathol; 2006 Jul; 30(7):871-7. PubMed ID: 16819330
[TBL] [Abstract][Full Text] [Related]
6. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
[TBL] [Abstract][Full Text] [Related]
7. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
[TBL] [Abstract][Full Text] [Related]
8. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus.
Sharma P; Falk GW; Weston AP; Reker D; Johnston M; Sampliner RE
Clin Gastroenterol Hepatol; 2006 May; 4(5):566-72. PubMed ID: 16630761
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of Barrett's high-grade dysplasia.
Weston AP; Sharma P; Topalovski M; Richards R; Cherian R; Dixon A
Am J Gastroenterol; 2000 Aug; 95(8):1888-93. PubMed ID: 10950031
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma.
Larghi A; Lightdale CJ; Ross AS; Fedi P; Hart J; Rotterdam H; Noffsinger A; Memeo L; Bhagat G; Waxman I
Endoscopy; 2007 Dec; 39(12):1086-91. PubMed ID: 17701854
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of dysplasia arising in Barrett's esophagus: a dynamic view.
Romagnoli R; Collard JM; Gutschow C; Yamusah N; Salizzoni M
J Am Coll Surg; 2003 Sep; 197(3):365-71. PubMed ID: 12946790
[TBL] [Abstract][Full Text] [Related]
12. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues.
Fang M; Lew E; Klein M; Sebo T; Su Y; Goyal R
Am J Gastroenterol; 2004 Oct; 99(10):1887-94. PubMed ID: 15447746
[TBL] [Abstract][Full Text] [Related]
13. [The influence of Barrett's esophagus on the clinical signs and postoperative results of GERD].
Endzinas Z; Mickevicius A; Kiudelis M
Zentralbl Chir; 2004 Apr; 129(2):99-103. PubMed ID: 15106039
[TBL] [Abstract][Full Text] [Related]
14. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or early cancer.
Foroulis CN; Thorpe JA
Eur J Cardiothorac Surg; 2006 Jan; 29(1):30-4. PubMed ID: 16337389
[TBL] [Abstract][Full Text] [Related]
16. Oesophagectomy remains the gold standard for treatment of high-grade dysplasia in Barrett's oesophagus.
Sujendran V; Sica G; Warren B; Maynard N
Eur J Cardiothorac Surg; 2005 Nov; 28(5):763-6. PubMed ID: 16188449
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic variation and outcome for high-grade gastric epithelial dysplasia.
Sarela AI; Scott N; Verbeke CS; Wyatt JI; Dexter SP; Sue-Ling HM; Guillou PJ
Arch Surg; 2005 Jul; 140(7):644-9. PubMed ID: 16027328
[TBL] [Abstract][Full Text] [Related]
18. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry.
Ganz RA; Overholt BF; Sharma VK; Fleischer DE; Shaheen NJ; Lightdale CJ; Freeman SR; Pruitt RE; Urayama SM; Gress F; Pavey DA; Branch MS; Savides TJ; Chang KJ; Muthusamy VR; Bohorfoush AG; Pace SC; DeMeester SR; Eysselein VE; Panjehpour M; Triadafilopoulos G;
Gastrointest Endosc; 2008 Jul; 68(1):35-40. PubMed ID: 18355819
[TBL] [Abstract][Full Text] [Related]
19. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD
Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
[TBL] [Abstract][Full Text] [Related]
20. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression.
Skacel M; Petras RE; Rybicki LA; Gramlich TL; Richter JE; Falk GW; Goldblum JR
Am J Gastroenterol; 2002 Oct; 97(10):2508-13. PubMed ID: 12385431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
